Successfully Completed Phase I Single Dose Study for GXV-001
2023/1/10
GEXVal Inc.January 10, 2023 GEXVal Inc. is conducting a Phase I study for GXV-001, a new drug candidate, throu […]
GEXVal Gave Presentation at KIRIN
2022/12/27
GEXVal Inc.December 27, 2022 Juran Kato, PhD, president and CEO of GEXVal ., was invited by Kirin Holdings Com […]
GEXVal CEO Won a Prize Outstanding Leadership Awards at health2.0 CONFERENCE
2022/12/16
GEXVal Inc.December 16,2022 Juran Kato, PhD, president and CEO of GEXVal ., received an Outstanding Leadersh […]
GEXVal Gives a Presentation at "Let's Talk with VCs" Series Organized by Link-J
2022/11/25
GEXVal Inc.November 25, 2022 Juran Kato, PhD, founder, president and CEO of GEXVal ., will give a presentation […]